KA
GILD icon

Kovack Advisors’s Gilead Sciences GILD Stock Holding History

Kovack Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10
Closed -$2K – 474
2017
Q3 		$2K Buy
+10
New +$765 ﹤0.01% 350
2016
Q3 		– Sell
-6
Closed -$4K – 284
2016
Q2 		$4K Buy
+6
New +$532 ﹤0.01% 255
2015
Q4 		– Sell
-2
Closed -$1K – 245
2015
Q3 		$1K Buy
+2
New +$222 ﹤0.01% 217

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kovack Advisors's GILD Position: Q2 2026 in Review

Kovack Advisors reduced its Gilead Sciences (GILD) stake by 64% in Q2 2026, selling an estimated $1.5M and leaving 6,409 shares worth $809K. The position accounts for 0.04% of the portfolio, ranked #454.

Kovack Advisors first reported a position in GILD in Q3 2014 and has held it in 47 quarters since. The position peaked at $3.12M in Q4 2025. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Kovack Advisors held 6,409 shares of Gilead Sciences worth $809K as of Q2 2026.
  • Kovack Advisors sold 11,385 Gilead Sciences shares in Q2 2026, an estimated $1.5M.
  • Gilead Sciences made up 0.04% of Kovack Advisors's portfolio in Q2 2026, its #454 holding.
  • Kovack Advisors first reported a position in Gilead Sciences in Q3 2014 and has held it in 47 quarters since.
  • Kovack Advisors's Gilead Sciences position peaked at $3.12M in Q4 2025.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.